Clinical Trial Update: Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 safety study of sargramostim for mild cognitive impairment due to Alzheimer's disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• sargramostim (sargramostim)

Snippet

Sponsor: Sanofi | Conditions: Dementia Alzheimer's Type | Phase 2 | Status: WITHDRAWN